TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06075030: A Multicenter, Randomized, Open-label Study of AND017 for the Treatment of Cancer-Related Anemia Patients Receiving Chemotherapy

Sponsor: Kind Pharmaceuticals LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT06075030 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06075030 Rescue Dossier →